Drugs / TAK-510
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04731922 | Feb 2021 → Jul 2022 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04731922 ↗ |
| Route | Subcutaneous | “TAK-510 at starting dose of 5 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1.” NCT04731922 ↗ |